Overview

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Status:
Unknown status
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
To identify the efficiency of Irinotecan, Oxaliplatin, and S1 in patients with previously untreated local regional or metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Qingdao Central Hospital
Treatments:
Camptothecin
Irinotecan
Oxaliplatin